


Volume 12(2)
ISSN 0306-5251

pages 95-264
265P-286P

British Journal of Clinical Pharmacology

August 1981



Edited for the British Pharmacological Society by

C.T. Dollery (*Chairman*) A. Richens (*Secretary*)
Annmarie Hedges (*Press Editor*)

T.B. Binns	A.F. Lant
A. Breckenridge	G. Mawer
W. Watson Buchanan	D.G. McDevitt
D.B. Calne	A.N. Nicholson
T. Chard	F. O'Grady
J. Crooks	J.P. Payne
D.A.P. Evans	B.N.C. Prichard
C.F. George	M. Rawlins
A. Goldberg	J. Reid
D. Grahame-Smith	R.G. Shanks
I.W.B. Grant	F.O. Simpson
R.L. Hodge	J.R. Trounce
M.H. Lader	D.W. Vere
O.L. Wade	

Papers will be considered for publication on all aspects of drug action in man.

Manuscripts (two copies) should be sent to Professor A. Richens, Department of Pharmacology and Materia Medica, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN. The instructions to authors are printed in volume 1 (pages 3 to 6) of the journal. Details of the SI symbols for units can be found in the January 1974 issue (volume 50, pages 6 to 23) of the *British Journal of Pharmacology*.

British Journal of Clinical Pharmacology is published monthly by Scientific & Medical Division, Macmillan Publishers Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke 29242. ISSN 0306-5251.

Annual subscription: UK £75.00; USA & Canada, US\$185; Rest of world, £89; Airmail £102 (or equivalent in any other currency). (Orders must be accompanied by remittance. Prices correct at time of publication.)

Cheques should be made payable to Macmillan Journals Limited: Subscription Department, Brunel Road, Basingstoke, Hampshire RG21 2XS, England. Where appropriate, overseas subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment.

Enquiries concerning advertising space or rates should be addressed to: Advertisement Department, Macmillan Journals Limited, 4 Little Essex Street, London WC2R 3LF. Telephone: 01-836 6633.

Copyright © 1981 by the *British Journal of Clinical Pharmacology*. All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

METFORMIN KINETICS IN HEALTHY SUBJECTS AND IN PATIENTS WITH DIABETES MELLITUS

G.T. TUCKER, C. CASEY, P.J. PHILLIPS*, H. CONNOR, J.D. WARD & H.F. WOODS

University Department of Therapeutics,
The Royal Hallamshire Hospital, Sheffield, S10 2JF

- 1 The kinetics of metformin were studied after i.v. and oral administration in four healthy subjects and after oral administration in twelve maturity onset (Type II) diabetic patients.
- 2 After i.v. administration most of the dose was rapidly eliminated but with a mean 'terminal' $T_{1/2}$ of 4 h measured up to 12 h in plasma and of 16 h measured up to 60 h from the urinary excretion rate. On average, 80% of the dose was recovered as unchanged drug in the urine with none detected in the faeces.
- 3 After single oral doses (0.5 and 1.5 g), maximum plasma concentrations and urinary excretion rates were observed at about 2 h with urinary recoveries of unchanged drug of 35-50% and faecal recoveries of about 30%. Urinary recoveries were significantly lower after the higher dose. Absolute oral bioavailability was 50-60% of the dose.
- 4 Deconvolution analysis showed that after a short lag-time, the available oral dose was absorbed at an exponential rate over about 6 h. Implications for the design of prolonged release dosage forms are discussed.
- 5 Plasma metformin concentrations measured throughout the seventh and fourteenth days of continuous 0.5 g twice daily treatment were accurately predicted from single dose data, although a discrepancy between observed and predicted trough levels reflected the existence of a slow elimination phase. Implications of the latter for a gradual accumulation of metformin in peripheral tissues and a possible association with lactic acidosis are discussed.
- 6 Renal clearance of metformin was highly correlated with creatinine clearance. However, a weaker relationship between total oral clearance of the drug and creatinine clearance suggests that the latter may not always be a reliable indicator of potential metformin accumulation owing to variability in absorption and possibly non-renal clearance of the drug.

Introduction

Following the restrictions placed upon the prescribing of phenformin (phenylethylbiguanide) in some countries, and its removal from the market in others, metformin (N^1, N^1 -dimethylbiguanide) and buformin (N^1 -butylbiguanide) are now the most commonly prescribed oral hypoglycaemic drugs of the biguanide class. Metformin has been recommended as the drug of choice because the risk of developing lactic acidosis during treatment is less than that resulting from the use of phenformin (British Medical Journal, 1977; Phillips, Thomas & Harding, 1977; Bergman, Boman & Wiholm, 1978).

* On leave from the Institute of Medical and Veterinary Science, Adelaide, Australia. Present address: Flinders University Medical Centre, Adelaide, Australia

In spite of its widespread use, little is known about the pharmacokinetics of metformin. Two recent papers have described the kinetics in normal man (Sirtori *et al.*, 1978; Pentikäinen, Neuvonen & Penttilä, 1979) and in one of these (Sirtori *et al.*, 1978) special emphasis was placed upon the relationship between impairment of renal function and the resulting slowing of metformin clearance. The literature is deficient in information concerning the kinetics of metformin in patients with diabetes mellitus.

In this paper we describe the pharmacokinetics of metformin administered via the oral and intravenous routes in normal subjects and in patients with diabetes mellitus.

Methods

Protocol

Three groups of subjects were studied (Table 1).

Group I consisted of four healthy male volunteers who were given single intravenous and oral doses of metformin HCl on separate occasions at least 2 weeks apart, according to a cross-over design. The intravenous dose was 0.25 g given by constant-rate infusion over the course of 15 min and the oral doses were 0.5 g and 1.5 g, respectively, in the form of Glucophage® tablets from a single batch. The intravenous solution and tablets were analysed and found to contain between 98 and 100% of the stated dose. The oral doses were taken with breakfast. Drug concentrations were measured in serial samples of whole blood, plasma, urine and faeces. Blood samples, obtained by venepuncture without stasis, were collected up to 12 h (i.v. study) and 24 h (oral study); urine samples were collected up to 72 h and faecal samples to 5 days.

The purpose of these experiments was to assess: (I) the recovery of unchanged drug; (II) the rate and extent of oral bioavailability of metformin; (III) any dose-dependence in its kinetics and (IV) the distribution of the drug between plasma and blood cells.

Group II consisted of four newly diagnosed maturity onset (Type II) diabetic patients. They received a single 1.0 g oral dose (as Glucophage® tablets) fol-

lowed 3 days later by 0.5 g (p.o.) twice a day. The drug was taken with meals as is normally advised.

Metformin concentrations were determined in serial plasma samples up to 24 h and in serial urine samples up to 72 h after the first dose and in plasma samples during days 7 and 14 of continuous twice daily dosing.

The purpose of this experiment was: (I) to compare metformin kinetics in the patients with that in healthy subjects (Group I); (II) to assess the accumulation of the drug and the degree to which this could be predicted from single dose data.

Group III was composed of eight maturity onset (Type II) diabetic patients four of whom were taking chlorpropamide (Table 1). They were all given a single 1.0 g oral dose in the form of Glucophage® tablets. Metformin concentrations were measured in serial plasma samples up to 24 h and in serial urine samples up to 72 h.

The purpose of this experiment was to assess the relationship between metformin kinetics and renal function. Combining the data from all three groups gave information about metformin clearance over a range of creatinine clearance from 47 to 179 ml min⁻¹. (Table 1.)

These studies were approved by the local hospital Ethics Committee.

Drug analysis

Concentrations of unchanged metformin were meas-

Table 1 Clinical details of normal subjects and diabetic patients

Group	Subject	Age (years)	Sex	Weight (kg)	Height (cm)	Cl _{CR} ^a (ml min ⁻¹)	Other ^b drugs
I	1	34	M	66	108	113	—
	2	30	M	68	178	106	—
	3	30	M	64	175	145	—
	4	36	M	83	178	179	—
II	5	62	M	95	173	120	—
	6	68	M	74	160	85	M, N
	7	70	F	68	152	86	N
	8	46	M	90	179	168	—
III	9	70	M	73	168	51	P, C
	10	67	M	58	168	97	—
	11	68	F	78	173	85	M
	12	81	F	57	155	47	C
	13	73	F	64	127	57	A, C
	14	57	M	84	176	116	M
	15	70	M	81	168	72	C
	16	59	M	82	184	107	—

a creatinine clearance, determined by the Jaffé method using an Autoanalyser.

b A = atenolol;
N = Navidrex K;

C = chlorpropamide;
P = prochlorperazine

M = α-methyl dopa;

ured using a specific gas chromatographic method (Lennard *et al.*, 1978). Coefficients of variation of the assay were $\pm 9\%$ and $\pm 5\%$ at 50 ng ml^{-1} and $2 \text{ } \mu\text{g ml}^{-1}$, respectively. All samples were assayed in duplicate.

Plasma binding

The binding of metformin in plasma samples from healthy subjects, spiked with drug concentrations of 0.1 and $10 \text{ } \mu\text{g ml}^{-1}$ was determined using the Dianorm® equilibrium dialysis apparatus (Weder, Schildknecht & Kesselring, 1971). Samples were dialysed for 3 h at 37°C against phosphate buffer, pH 7.4, using 1.0 ml half-cells and a cellulose acetate membrane.

Pharmacokinetic analysis

Intravenous administration (Group I) Post-infusion plasma drug concentrations (C_{post}) were fitted by a triexponential equation:

$$C_{\text{post}} = \sum_{i=1}^3 C_i e^{-\lambda_i t} \quad (1)$$

Initial estimates of the coefficients C_i^1 and λ_i were obtained graphically by the method of residuals. The values were then refined using the Gauss-Newton iterative procedure incorporated in a modification of the IGP HARM package (Gomeni & Gomeni, 1978). Experimental data points were weighted according to the square of their reciprocal values. Assessment of the goodness of fit of computed data to observed data was based on plots of weighted residuals against time and the coefficient of determination (Boxenbaum, Riegelman & Elashoff, 1974).

Values of the coefficients C_i^1 were corrected to those expected following an instantaneous bolus injection (C_i) using equation 2:

$$C_i = C_i^1 \left(\frac{\lambda_i \tau}{1 - e^{-\lambda_i \tau}} \right) \quad (2)$$

where τ is the infusion time.

Total plasma clearance (Cl) was calculated from:

$$\text{Cl} = \frac{D}{\text{AUC}} \quad (3)$$

where D is the dose and AUC is the area under the plasma drug concentration-time curve extrapolated to infinite time and given by:

$$\text{AUC} = \sum_{i=1}^3 \frac{C_i}{\lambda_i} \quad (4)$$

$$\text{Cl}_R = \frac{\text{Ae}(12)}{\text{AUC}(12)} \quad (5)$$

where $\text{Ae}(12)$ is the amount of unchanged drug excreted in the urine up to 12 h and $\text{AUC}(12)$ is the area under the plasma drug concentration-time curve up to 12 h and given by:

$$\text{AUC}(12) = \text{AUC} - \frac{C(12)}{\lambda_3} \quad (6)$$

where $C(12)$ is the estimated plasma drug concentration at 12 h after a bolus injection.

The fraction of the dose excreted as unchanged drug (f_e) was calculated from:

$$f_e = \frac{\text{Ae}(72)}{D} \quad (7)$$

where $\text{Ae}(72)$ is the urinary recovery of unchanged drug at 12 h.

The volume of distribution at pseudoequilibrium during the terminal log-linear phase (V) was calculated from:

$$V = \frac{\text{Cl}}{\lambda_3} \quad (8)$$

Urinary excretion rates were also fitted by a triexponential equation using non-linear least squares regression with weighting by the square of reciprocal values.

Oral administration

(a) **Single dose (Groups I-III)** Plasma drug concentration-time curves were fitted graphically by a triexponential equation with one negative and two positive terms in a similar manner to the i.v. data. When subjected to non-linear least squares regression analysis the solutions for many of the data sets converged on an equation consisting of a negative and a positive exponential term plus a constant term. The latter reflected the slow disappearance of metformin between 12 and 24 h and the lack of data points between these times. In view of this deficiency in data collection an approximate 'terminal' $T_{1/2}$ is reported, based upon the initial graphical estimates.

Oral bioavailability was calculated in two ways, using plasma data (F_p) by equation 9 and using urine data (F_{ur}) by equation 10:

$$F_p = \frac{[\text{AUC}(12)_{\text{po}}] \cdot D}{[\text{AUC}(12)] \cdot D_{\text{po}}} \quad (9)$$

where D_{po} in the oral dose and $\text{AUC}(12)_{\text{po}}$ is the area under the plasma drug concentration-time curve up to 12 h after the oral dose calculated by the trapezoidal rule. D and $\text{AUC}(12)$ refer to intravenous ad-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.